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A b s t r a c t  Several lines of  evidence suggest that dopa- 
mine might  be involved in anxiety states. In the present 
study we assessed the growth hormone (GH) response to 
0.5 mg apomorphine (a dopaminergic agonist) in 10 male 
drug-free inpatients meeting Research Diagnostic Criteria 
for panic disorder who were compared with 10 male ma- 
jor  depressive inpatients and 10 male normal  controls. 
The three groups differed significantly in the GH peak re- 
sponse (mean + SD): 27.8 + 12.5 ng/ml in panics, 5.4 + 
4.0 ng/ml in major  depressives, and 25.8 + 11.3 ng/ml in 
normal controls (F(2,27) = 15.3; P = 0.00003). Although 
there were significant differences between panics and ma- 
jor depressives (P = 0.00004), and between major  depres- 
sives and controls (P = 0.00004), panics did not signifi- 
cantly differ f rom controls. These results do not support 
the hypothesis  of  an overlap between panic and affective 
disorders, and suggest that the hypotha lamo-GH-soma-  
tomedin axis could be intact in panic disorder. 
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Introduction 
Current hypothesis  about the et iopathology of  panic disor- 
der (PD) principally involve serotonergic, noradrenergic, 
and benzodiazepine systems (Pecknold and Luthe 1990; 
Charney et al. 1990; Nutt  et al. 1990). A large body of  
data also suggests a role for the dopaminergic system as a 
possible etiological factor in PD. Indeed, Stein et al. 
(1990) showed a higher incidence of  panic attacks in pa- 
tients with Parkinson 's  disease. Roy-Byrne  et al. (1985 a) 
reported indirect biological  support for increased dopa- 
minergic functioning in PD patients by demonstrat ing a 
blunted thyrotropin-stimulating hormone  (TSH) and pro- 
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lactin (PRL) response to thyrotropin-releasing hormone 
(TRH). Recently, we reported a significantly higher growth 
hormone  (GH) response to apomorphine,  a dopaminergic 
agonist, in PD patients compared with minor  and major  
depressives suggesting an increased dopamine receptor 
sensitivity in PD (Pitchot et al. 1992). Moreover, this study 
did not support the hypothesis o f  a c o m m o n  link between 
panic and affective disorders. However,  the lack o f  a nor- 
mal control group represented a major  methodological  
problem. In the present study we compare  PD patients to 
major  depressives and normal controls. 
Subjects and methods 
Ten male inpatients (mean age 36.7 years; SD 10.2 years) meeting 
Research Diagnostic Criteria (RDC) for panic disorder without 
major depression were admitted to the Psychiatric Unit of the Uni- 
versity Hospital of Liege, Belgium. All patients had a score less 
than 12 on the 17-item Hamilton Depression Scale (Hamilton 
1960). The PD patients were compared with 10 male major-de- 
pressive inpatients (mean age 36.6 years; SD 9.2 years) according 
to RDC with a score of 25.6 (SD 5.3) on the 17-item Hamilton De- 
pression Scale, and 10 male normal controls (mean age 25.4 years; 
SD 7.9 years). There was no significant difference in mean weight 
between the three groups. All patients were free of medical illness 
and assessed after a drug-free period of at least 2 weeks. Patients 
with a basal systolic blood pressure less than 100 mmHg were ex- 
cluded from the study. Moreover, to be included patients had to 
present basal GH level less than 5 ng/ml before the neuroendocrine 
test. The exclusion of subjects with a basal GH value greater than 
5 ng/ml was recommended by Laakmann (1990) who demon- 
strated that "prestimulator" healthy volunteers responded signifi- 
cantly less to a noradrenergic challenge than healthy volunteers 
with low basal values. Finally, all patients were fully informed of 
the study and gave their consent. 
The apomorphine test was performed in all subjects at bedrest 
after an overnight fast. At 7 A.M. an indwelling catheter was in- 
serted into a forearm vein. Blood samples of 10 ml were collected 
at -20, 0, 20, 40, 60, and 120 min after injection at 8 A.M. of 0.5 
mg apomorphine diluted in saline to obtain 0.5 ml subcutaneously. 
The GH was measured with a double antibody radioimmunoas- 
say (Franchimont 1968), with intraassay and interassay coeffi- 
cients of variation of 13.3 + 4.7% and 14.8 + 9.6%, respectively, 
and a detection limit of 0.2 ng/ml. The GH responses to apomor- 
phine were assessed by GH peak values following injection. The 
analysis was performed using absolute GH values as well as dif- 
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ferences related to basal (tO) levels (relative values). Because the 
correlations between absolute and relative values were very high 
(r > 0.98), only the absolute values are reported here. The responses 
of the patients were compared using a single analysis of variance 
(ANOVA) with posthoc analyses. Moreover, in order to control 
the possible influence of some outliers on the positive findings, the 
comparison was also performed by means of the Wilcoxon non- 
parametric test. 
Results 
All patients exhibited baseline GH values below 3 ng/ml. 
The three groups differed significantly in the GH peak re- 
sponse (mean + SD): 27.8 + 12.5 ng/ml in panics, 5.4 + 
4.0 ng/ml in major depressives, and 25.8 + 11.3 ng/ml in 
normal controls (F(2,27) = 15.3; P = 0.00003); (Figure 1). 
While there were significant differences between panics 
and major depressives (F(1, 18) -= 28.9; P = 0.00004), and 
between major depressives and controls (F(1, 18) = 28.8; 
P = 0.00004), panics did not significantly differ from con- 
trols (F(1, 18) = 0.13; n.s.). The analysis using the Wil- 
coxon nonparametric test confirmed that there were sig- 
nificant differences between panics and major depressives 
(z = -3.36; P < 0.001), and between major depressives 
and controls (z = 3.6; P < 0.001), but panics did not sig- 





















Panics Major Controls 
depressives 
Fig. 1 Distribution of growth hormone peak values after apomor- 
phine in 10 panics, 10 major depressives, and 10 normal controls 
Discussion 
The results of the present study show that there is no over- 
lap between panic and affective disorders in relation to 
GH response to apomorphine, which is in line with previ- 
ous studies assessing other biological parameters, such as 
sleep architecture (Akiskal et al. 1984), platelet imipra- 
mine binding (Pecknold and Luthe 1990), TSH responses 
to TRH (Stein and Uhde 1991), and dexamethasone sup- 
pression test (Roy-Byrne et al. 1985b) which were found 
to differentiate panic and depressed patients. Moreover, 
the present study does not provide evidence of a dopamin- 
ergic overactivity in panic disorder. In 1986 Roy-Byrne et 
al. did not find any significant difference in the plasmatic 
concentrations of the dopamine metabolite homovanillic 
acid (HVA) between PD patients and controls. However, 
higher plasma HVA concentrations were found in a sub- 
group of PD patients characterized by a higher level of 
anxiety and a greater number of panic attacks in the past 
year. In fact, dopamine seems to be implicated in the con- 
trol of anxiety symptoms, but does not play a major role 
as an etiological factor in panic disorder. In contrast, Gur- 
guis et al. (1991) found lower plasma HVA levels sug- 
gesting decreased dopaminergic function in PD patients; 
however, this finding could be related to concomitant de- 
pression. 
The major finding of this study is that PD patients pre- 
sent normal GH responses to apomorphine, which con- 
trasts with several studies reporting blunted responses 
across different probes (clonidine, yohimbine, caffeine, 
glucose, GHRH). On the basis of these last observations, 
Uhde et al. (1992) raised the possibility that panic disor- 
der might be a condition characterized by an intrinsic ab- 
normality in the hypothalamic-GH-somatomedin axis. The 
results of the current study suggest that the axis could be 
intact in PD patients. Moreover, our data provide evidence 
that the blunted GH response to clonidine observed in 
panic disorder suggests an o~2-receptor-based abnormality 
in panic disorder, rather than a global alteration in GH 
function. 
A major pitfall of this study is the possible inadequacy 
of the drug-free wash-out period of 2 weeks, which could 
be insufficient. Indeed, tricyclic antidepressants are known 
to impair the GH response to clonidine for periods longer 
than 3 weeks following their discontinuation (Schittecatte 
et al. 1989) and could influence GH response to apomor- 
phine. However, recently we assessed the GH response to 
apomorphine in 11 male DSM-III-R major depressive in- 
patients who had never received antidepressant therapy 
compared with 11 normal controls and 11 major depres- 
sive inpatients drug-free for at least 2 weeks, and demon- 
strated that a wash-out period of 2 weeks could be suffi- 
cient in studies assessing the GH response to apomor- 
phine (Pitchot et al. 1995). 
In conclusion, these results suggest that the GH re- 
sponse to apomorphine is able to differentiate panic and 
depressed patients. Moreover, the hypothesis of a dopamin- 
ergic hyperactivity in panic disorder is not supported by 
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the results  o f  the present  study. Our  data  also suggest  that 
the h y p o t h a l a m i c - G H - s o m a t o m e d i n  axis is intact  in panic  
disorder. However ,  our sample  is small ,  and therefore these 
results  should  be taken with caution. 
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